Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
40.18
+0.14 (0.35%)
At close: Nov 12, 2024, 4:00 PM
40.10
-0.08 (-0.20%)
Pre-market: Nov 13, 2024, 4:02 AM EST
Legend Biotech Employees
Legend Biotech had 1,826 employees as of December 31, 2023. The number of employees increased by 436 or 31.37% compared to the previous year.
Employees
1,826
Change (1Y)
436
Growth (1Y)
31.37%
Revenue / Employee
$284,876
Profits / Employee
-$190,651
Market Cap
7.40B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,826 | 436 | 31.37% |
Dec 31, 2022 | 1,390 | 319 | 29.79% |
Dec 31, 2021 | 1,071 | 189 | 21.43% |
Dec 31, 2020 | 882 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Jazz Pharmaceuticals | 2,800 |
Glaukos | 907 |
Ascendis Pharma | 879 |
Madrigal Pharmaceuticals | 376 |
LEGN News
- 13 hours ago - Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 7 days ago - Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma - GlobeNewsWire
- 8 days ago - Legend Biotech Appoints Alan Bash as President of CARVYKTI® - GlobeNewsWire
- 5 weeks ago - Stock Picks From Seeking Alpha's September 2024 New Analysts - Seeking Alpha
- 5 weeks ago - Legend Biotech to set up new R&D facility in Philadelphia - Reuters
- 5 weeks ago - Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia - GlobeNewsWire
- 6 weeks ago - Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients - Benzinga